New Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demonstrate robust 2-year results in the treatment of adults and adolescents with plaque psoriasis

{
  "signal_id": "8afb08db-5b91-1cb3-ceef-ca9f13d5e324",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-10-09T11:00:00+00:00",
  "company": {
    "name": "Johnson & Johnson",
    "domain": "jnj.com"
  },
  "data": {
    "url": "https://www.prnewswire.com/news-releases/new-johnson--johnson-icotyde-icotrokinra-long-term-data-demonstrate-robust-2-year-results-in-the-treatment-of-adults-and-adolescents-with-plaque-psoriasis-302902715.html",
    "title": "New Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demonstrate robust 2-year results in the treatment of adults and adolescents with plaque psoriasis",
    "excerpt": "SPRING HOUSE, Pa. , Oct. 9, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced new two-year results from the Phase 3 ICONIC-LEAD a study evaluating ICOTYDE ® (icotrokinra), the first and only targeted oral peptide that precisely blocks the IL-23 receptor 1 , in adults and pediatric patients 12 years of age and older (adolescents) with moderate-to-severe plaque psoriasis. These data, presented at Fall Clinical Dermatology (FCD) 2026, demonstrated consistently high levels of skin clearance and patient-reported symptom improvement at Week 112, with no new safety signals identified. 2 \"As plaque psoriasis is a chronic lifelong disease, durable results are essential in therapy selection. With two-year data that show long-term skin clearance and a consistent safety profile, ICOTYDE is transforming how we think about plaque psoriasis treatment,\" said Mark Lebwohl, M.D., Professor and Chair Emeritus, Department of Dermatology, Icahn School of Medicine at Mount Sinai and ICONIC-LEAD study investigator. b \"I'm excited to have this practice-changing targeted oral peptide as a first-line systemic therapy for both my adult and adolescent patients.\" ICOTYDE clinical data highlights 2 \"These long-term results affirm that ICOTYDE, as the first and only targeted oral peptide, represents a groundbreaking shift in the treatment of plaque psoriasis,\" said David M. Lee, M.D...",
    "product": "ICOTYDE",
    "summary": "Johnson & Johnson is evaluating ICOTYDE (icotrokinra) in clinical studies for active psoriatic arthritis, ulcerative colitis, and Crohn's disease.",
    "location": "Spring House, Pennsylvania, USA",
    "planning": true,
    "image_url": "https://mmx.prnewswire.com/media/MS225644/Johnson-and-Johnson-Logo-v1.jpg?id=OA2992766&p=facebook",
    "confidence": 0.85,
    "product_data": {
      "name": "ICOTYDE",
      "full_text": "ICOTYDE ® (icotrokinra)",
      "fuzzy_match": false
    },
    "product_tags": [
      "general_technology",
      "medical"
    ],
    "published_at": "2026-10-09T11:00:00Z",
    "location_data": [
      {
        "city": "Spring House",
        "state": "Pennsylvania",
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "article_sentence": "ICOTYDE is also being studied in active psoriatic arthritis, moderately to severely active ulcerative colitis and moderately to severely active Crohn's disease."
  }
}

curl https://signals.autobound.ai/v1/signals/8afb08db-5b91-1cb3-ceef-ca9f13d5e324 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"jnj.com","limit":20}'